News

Updated international guidelines to help clinicians diagnose idiopathic pulmonary fibrosis (IPF) were recently published in the American Journal of Respiratory and Critical Care Medicine. These new 2018 clinical practice recommendations are the result of a collaborative effort between experts from four major respiratory societies — the American…

Modifying the dose of Esbriet (pirfenidone) can effectively reduce the number of treatment-related adverse events without affecting the drug’s potential to manage idiopathic pulmonary fibrosis (IPF), a new retrospective analysis of data from Phase 3 clinical trials shows. The findings of this recent post-hoc analysis were published in…

The idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 eased lung fibrosis (scarring) in a mouse model, according to South Korea-based Bridge Biotherapeutics. The company believes that BBT-877 may become the “best-in-class” medication for IPF. Data from a preclinical study on BBT-877 was presented at the 2nd Annual IPF…

A plant-based medicine called quercetin reversed pulmonary fibrosis in a mouse model likely by reducing the burden of growth-arrested and fibrosis-promoting cells, called senescent cells, in the animals’ lungs, researchers report. Findings were published in the study, “Quercetin enhances ligand-induced apoptosis in senescent IPF fibroblasts and reduces lung…

Surgery for lung cancer should be carefully considered in patients who also have idiopathic pulmonary fibrosis (IPF), because it is associated with poor outcomes, a study shows. The study, “Survival after repeated surgery for lung cancer with idiopathic pulmonary fibrosis: a retrospective study,” was published in the journal…